TECHNE Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. TECHNE Corporation, along with its subsidiaries, is engaged in the development, manufacture, and sale of biotechnology products and hematology calibrators and controls. The Company’s activities are conducted, through its wholly owned subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems), and BiosPacific, Inc. (BioPacific). The Company distributes the biotechnology products in Europe, through its wholly owned United Kingdom-based subsidiary, R&D Systems Europe Ltd. (R&D Europe). The Company distributes biotechnology products in the People’s Republic of China, through its wholly owned subsidiary, R&D Systems China, Co. Ltd. (R&D China). The Company operates in three business segments: biotechnology, R&D Europe and hematology.

Bionovo, Inc. company was founded in 2002 and is based in Emeryville, California. Bionovo, Inc. is a clinical stage drug discovery and development company focusing on women’s health and cancer. The Company designs drugs derived from botanical sources, which have mechanisms of action. The Company’s drug candidate, Menerba, represents a class of receptor sub-type selective estrogen receptor modulator (SERM) for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed Menerba to selectively modulate estrogen receptor beta (ERβ). In preclinical studies, Menerba inhibited tumor growth, as well as bone resorption known to cause osteoporosis, which is developed during menopause. The Company was developing BZL101, an oral anti-cancer agent for advanced breast cancer during the year ended December 31, 2008. BZL101 is designed to take advantage of the metabolism of cancer cells. BZL101 inhibits glycolysis, a metabolic pathway on which cancer cells rely.

Tropical Oasis hopes to be exactly that, offering much needed refreshment to bodies in need of liquid. Through its three brands, Tropical Oasis, Liquid Solutions, and Radical Performance Technology, the company offers a variety of nutritional and sports drinks which can boost energy, replenish certain nutrients and vitamins, and assist in weight loss efforts.

The pros at ProPharma Partners offer advice to biotechnology and pharmaceutical companies on everything from corporate strategy to clinical trials. The consulting firm, which is the European arm of US-based ProPharma Partners Group, assists companies with negotiating licensing deals, corporate partnerships, and mergers and acquisitions. ProPharma also helps its clients complete FDA regulatory applications in order to register and market newly-developed drug products. The group has offices in North America, Europe, and Japan, from which it serves such clients as Cambridge Laboratories, King Pharmaceuticals, Metabolex, ReGen Therapeutics Plc, and Replidyne.

Progenics Pharmaceuticals, Inc. company was founded in 1986 and is based in Tarrytown, New York. Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company, in collaboration with Wyeth Pharmaceuticals, provides RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation (OIC) in advanced illness patients receiving palliative care. It is also developing the HIV entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the entry co-receptor, CCR5, and is in Phase II clinical testing; and a novel HCV entry inhibitor, PRO 206. In addition, Progenics Pharmaceuticals is conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate (ADC) designed to selectively target prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as in blood vessels supplying non-prostatic solid tumors; and various Phase I clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

AstraZeneca Czech Republic is a subsidiary of the international pharmaceutical behemoth known as AstraZeneca. It markets products such as heartburn reliever Nexium, local anesthetic Xylocaine, and endometriosis treatment Zoladex in the Czech Republic. It also conducts clinical trials on potential drug candidates in other parts of Central and Eastern Europe, such as Bulgaria, Hungary, Poland, Romania, and Slovenia. It focuses its research efforts primarily on the medical fields of gastroenterology, gynecology, and oncology, as well as bone and joint, cardiovascular, infectious, and respiratory diseases.

Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts. Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; and M118, an anticoagulant. The company also involves in developing generic or biosimilar glycoprotein products. Momenta Pharmaceuticals has collaborations with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002.

Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, HIV, and inflammatory diseases. The company's lede program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, multiple myeloma, and prostate cancer. Incyte has several other products in clinical trial stages, including a CCR5 antagonist designed to prevent the entry of HIV into target cells.

NextGen Group, which does business as NextGen Sciences, puts proteins to the test. The research and development company provides protein analysis services for biotechnology and pharmaceutical customers around the world. Specific services include biomarker discovery and assay development, which are often used in the drug development process to test preclinical and clinical samples for therapeutic efficacy and safety. NextGen's biomarker projects focus on Alzheimer's disease and oncology, among other therapeutic areas. The group has operations in the US and the UK.

Genitope is a drug development company in arrested development. It had hoped to find new ways to fight cancer with old weapons, but now it is just hoping to find a future. The company was researching immunotherapy treatments for cancer, using the body's own immune system to fight tumors. Genitope's leading drug candidate, MyVax, was a patient-specific immunotherapy that would specify the genetic makeup of the tumor, activate the patient's immune system to attack it, and cause no damage to cells other than the tumor. However, the drug did not do well in early clinical trials, and when the FDA requested additional trials for further review, Genitope chose to scrap the whole program.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.